Abbott Laboratories logo

Abbott Laboratories (ABT)

Market Closed
24 Feb, 20:00
NYSE NYSE
$
114. 58
-0.71
-0.62%
$
195.3B Market Cap
36.49 P/E Ratio
0.79% Div Yield
9,001,232 Volume
4.44 Eps
$ 115.29
Previous Close
Day Range
113.82 115.37
Year Range
105.27 141.23
Want to track ABT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ABT earnings report is expected in 48 days (14 Apr 2026)
ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System

ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System

Abbott's Coronary IVL System wins FDA IDE nod, offering a potential new treatment for arterial calcium blockages.

Zacks | 11 months ago
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know

Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know

Abbott (ABT) reachead $127.21 at the closing of the latest trading day, reflecting a +0.69% change compared to its last close.

Zacks | 11 months ago
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 11 months ago
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.

Zacks | 11 months ago
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks | 11 months ago
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?

Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?

ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.

Zacks | 11 months ago
Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees

Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees

Abbott Laboratories is undervalued by the market, despite its strong fundamentals and strategic moves in high-growth areas like diabetes care and weight-loss treatments. The company boasts a high net income margin of 31.95% and generates over $8.5 billion in cash from operations, providing significant flexibility. Abbott's FreeStyle Libre system and new Protality brand highlight its long-term growth potential in diabetes care and weight-loss treatment markets.

Seekingalpha | 11 months ago
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Zacks | 11 months ago
2 Dependable Dividend Stocks That Can Pay You for Life

2 Dependable Dividend Stocks That Can Pay You for Life

What makes an outstanding dividend stock? High yields can seem attractive to income seekers, but unless a company has a steady, reliable business, payout cuts are a real possibility no matter how juicy its dividend yield.

Fool | 11 months ago
Strong Earnings Lift Abbott Laboratories Shares

Strong Earnings Lift Abbott Laboratories Shares

Health care company Abbott Laboratories (ABT) increases sales, earnings around the globe.

Fxempire | 11 months ago
My Best Dividend Aristocrats For March 2025

My Best Dividend Aristocrats For March 2025

The ProShares S&P 500 Dividend Aristocrat ETF kicks off 2025 on a bright note with a gain of 2.81% in January. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 43 months of tracking these strategies, one strategy is generating a CAGR superior to NOBL.

Seekingalpha | 0 year ago
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks | 0 year ago
Loading...
Load More